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€287.96: 55% private expenses and 45% charged to NHS. Hos-
pitalizations created the highest burden (22%, NHS) followed
by home-care and transport (both private). In the last year
26 patients (33%) varied their occupational status due to pain.
Fifty-eight (73%) patients required a caregiver; caregivers were
absent from work in 80% of cases. A strong impairment in
baseline HR-QoL was documented. Patients reported an average
value of 37 in the EQ-VAS (‘pain/discomfort’ and ‘usual activi-
ties’ are the most impaired domains), using the UK conversion
values the mean utility score was 0.07, using the Catalonian it
was 0.10. According to the Oswestry questionnaire, 44% of
patients were considered crippled and 39% severely disabled.
The physical role was the most impaired dimension as measured
with the SF-36. CONCLUSIONS: Our baseline analysis demon-
strates FBSS is a very expensive disease that severely impairs
HR-QoL. Future analyses will evaluate the cost-effectiveness of
SCS and CMM in the treatment of FBSS.
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OBJECTIVES: To evaluate the cost-effectiveness of fentanyl ITS
(iontophoretic transdermal system—IONSYSTM) versus epidural
analgesia (EA) or intravenous patient-controlled analgesia (IV-
PCA) for acute post-operative pain management (POPM) from a
Finnish hospital perspective. METHODS: The cost-effectiveness
of IONSYSTM was assessed using a decision analytic model esti-
mating costs (2008€) and POPM patient outcomes (pain relief,
minor and major POPM-related complications) from surgery
to discharge. Groups receiving 1, 2 or 3 day(s) of IV-PCA or EA
were compared to groups receiving respectively 1, 2 or 3 day(s)
of IONSYSTM. Pain relief data were derived from clinical trials
and published literature. Complication rates were predicted from
a longitudinal hospital database. Resource use included drugs,
consumables, equipment, POPM-related complications and staff
time, the latter derived from expert panels and a literature review.
Costs were based on ofﬁcial tariffs and price lists. RESULTS: The
costs of IONSYSTM for 1, 2 or 3-day groups were €1,825, €2,240
and €2,655. For 1 day of IV-PCA and 1, 2, 3 day(s) of EA
respectively, savings were €70, and €164, €167, €174. For 2 or 3
days of IV-PCA respectively additional costs were €19 and €105.
The percentage of complication-free patients was consistently
higher with IONSYSTM as regards minor and major complica-
tions with increment ranges of [1.44%, 3.95%] and [0.04%,
2.29%], respectively. The percentage of patients reporting no or
mild pain with IONSYSTM was the same as with IV-PCA and
lower than with epidural with respective increments for 1, 2 and
3-day groups of -4.02%, -4.33% and -5.26%. CONCLU-
SIONS: Compared to EA, IONSYSTM offers lower costs and
fewer complications. EA however offers improved pain relief.
Compared to IV-PCA, IONSYSTM dominates the 1-day group
and for the 2 and 3-day groups offers fewer complications at a
higher cost.
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OBJECTIVES: Health Technology Assessment to evaluate the
medical effectiveness and cost-effectiveness of bariatric surgical
procedures in the therapy of morbid obesity in adults compared
to standard interventions. METHODS: Systematic literature
review (published since 2001), targeting adult subjects with
morbid obesity (BMI >= 40 kg/m2 or BMI >= 35 kg/m2 with
severe comorbidities). Relevant publications are identiﬁed by
means of a structured search of 28 databases (e.g. Medline,
Embase, Cochrane Central) on November 12th, 2007. In addition
a manual search of identiﬁed reference lists was conducted. Titles
and abstracts of the identiﬁed publications have been indepen-
dently screened by two experts on evidence based medicine
and health economics. The methodological quality of included
studies have been assessed using the criteria recommended by
the Scottish Intercollegiate Guideline Network (SIGN) Grading
Review Group. Randomised as well as non-randomised studies
are included, case reports and series are not considered. The
methodological quality of the economic publications has been
assesed using checklists of the German Scientiﬁc Working Group
of Technology Assessment for Health Care and the methodologi-
cal guide of the EURONHEED project. RESULTS: Among 5910
retrieved publications, 25 medical articles and seven health eco-
nomic studies met the inclusion criteria. Among the included
medical publications are nine RCTs, 13 papers on non-
randomised clinical trials, and three systematic reviews with
meta-analysis. Within the economic assessment, three CEA and
four systematic reviews have been identiﬁed. Three of the non-
randomised studies assess bariatric vs. conventional procedures.
All other studies compare different surgical procedures among
each other. Follow-up time varies between one and ﬁve years in
the RCT and goes up to eleven years in one clinical trial. Both
medical studies assessing effectiveness of bariatric vs. conven-
tional procedures show a signiﬁcant greater weight loss after
surgery and decline in comorbidities. Diabetes incidence after ten
years is lower in the surgery group, but no signiﬁcant differences
can be seen for hypertension, dislipoproteinemia. Among the
economics publications, three studies evaluated the cost-
effectiveness of certain bariatric surgeries. One study examined
two bariatric operations, adjustable gastric banding and gastric
bypass, for the treatment of obesity in patients with Type 2
diabetes mellitusOne of the studies included deals with a com-
parison of GBP vs. no treatment, whereas the other compares the
two surgical procedures VBG and AGB among each other.
Furthermore, four systematic literature reviews are among the
included economic publications, estimating the cost-effectiveness
of bariatric treatments based on published data. The focus of
the reviews lies both, on the comparison of the cost-effectiveness
among the bariatric procedures, as well as on the comparison to
no treatment at all. CONCLUSIONS: The short and medium
term effectiveness of bariatric procedures on weight loss can be
assumed and is cost-effective. The weight loss is generally accom-
panied by a reduction of comorbidities, in particular diabetes,
and a decreased overall mortality. There is a lack of studies that
focus long term effects and costs. Therefore, based on the avail-
able literature no recommendation can be given with respect to
the choice of a certain bariatric procedure in usual care or to the
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selection of particular groups of patients. However, the present
results can be seen as a basis for discussion about the very
restrictive practice regarding decisions on reinbursability of bari-
atric procedures. Further more, comprehensive quality assurance
is needed, including the implementation of competence centres
and the ﬁxing of minimum amounts for procedures. In this
context the long term assessment and evaluation of all patients
and their course of disease is necessary, aiming at the highest
possible effectiveness of medical treatment and still allowing for
economic limits.
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OBJECTIVES: The aim of this research was to evaluate the
cost-effectiveness of duloxetine as an additional treatment option
in the management of ﬁbromyalgia (FM), assessed from an NHS
Scotland health care system perspective. METHODS: We used a
3-year health state transition model to represent the sequential
drug management of patients with FM. Guidelines, evidence
reviews and clinical opinion were used to deﬁne a standard
treatment for Scotland based on tricyclic antidepressants (TCAs)
with switching to second-generation antidepressants (SSRIs or
SNRIs). The model considered two levels of pain response based
on an 11-point severity scale (0 = ‘no pain’ to 10 = ‘worst pain
possible’): 30% (response) and 50% (full response) change
from baseline score. Clinical efﬁcacy and discontinuation data
were taken from a systematic literature review and an adjusted
indirect meta-analysis based on placebo-controlled trials of FM
treatments. Utility data were linked to pain severity using trial-
based EQ-5D data collected from patients in the duloxetine
studies. Costing was based on 2006. Annual discounting was
applied equally at 3.5%. RESULTS: The ﬁrst-line use of dulox-
etine resulted in approximately 67 additional quality-adjusted
life years (QALYs) per 1000 patients, achieved at an additional
cost of £397,360. This corresponded to a cost per QALY of
£5950 compared to current standard treatment without dulox-
etine. These results were robust to both deterministic and proba-
bilistic sensitivity analyses, demonstrating a 70% probability of
the ICER falling below £15,000 per QALY. A step-wise analysis
reported a cost per QALY of £4847 for ﬁrst-line duloxetine
versus second-line treatment and £7360 versus third-line treat-
ment. CONCLUSIONS: There is currently a signiﬁcant unmet
need for patients with poorly controlled FM where pain is a
predominant symptom. These analyses show that the introduc-
tion of duloxetine into the standard treatment sequence for FM
could provide additional patient beneﬁts which should be con-
sidered cost-effective when compared to commonly adopted
thresholds.
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OBJECTIVES: Beneﬂur®, whose active principle is ﬂudarabine,
has an oral and an intravenous (i.v.) formulation. The objective
of the present study was to compare the efﬁciency of both
formulations by means of a cost-minimization analysis in the
treatment of B-cell chronic lymphocytic leukaemia (CLL) in
Spain. METHODS: Existence of previous clinical evidence on
the therapeutic equivalence between both ﬂudarabine formula-
tions justiﬁed a cost-minimization analysis to compare efﬁ-
ciency. The National Health System (NHS) perspective was
taken including only direct costs. Also indirect costs were con-
sidered allowing a societal viewpoint. Data on resources use
were obtained from published literature and through an expert
panel. Unit costs were obtained from Spanish costs databases.
Generic i.v. ﬂudarabine cost was used. The model was built in
Microsoft Excel and a sensitivity analysis by means of two dif-
ferent techniques (scenario analysis and Monte-Carlo Simula-
tion) was performed to ensure robustness of results. RESULTS:
Although acquisition costs for oral ﬂudarabine are higher than
for i.v. ﬂudarabine, higher administration costs for the i.v. for-
mulation due to hospital administration and adverse event
costs compensate them, resulting in net savings for the NHS of
€2152 and €1322 using the oral formulation (baseline sce-
nario), in monotherapy and in combined therapy respectively.
The range of savings obtained through the scenario analysis
was: €1024 €3280 for monotherapy and €617 €2027
for combined therapy. Indirect costs, i.e. lost productivity,
charge only i.v. ﬂudarabine, adding extra savings to the oral
formulation. Monte-Carlo results conﬁrmed model robustness.
CONCLUSIONS: Oral ﬂudarabine has equivalent efﬁcacy and
an improved safety proﬁle than intravenous ﬂudarabine
showing total lower costs both in monotherapy and in combi-
nation with cyclophosphamide, from the perspective of the
National Health System in Spain. Hence, oral ﬂudarabine
should be administered instead of intravenous ﬂudarabine
unless contra-indicated.
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OBJECTIVES: Chronic back and leg pain results in patients’
loss of function, reduced QoL and increased societal costs. The
objective was to assess health-related QoL (HRQoL) and health
resource utilization in failed back surgery syndrome patients. A
comparison of spinal cord stimulation plus non-surgical conven-
tional medical management (SCS group) versus non-surgical con-
ventional medical management alone (CMM group) was made
from the Spanish National Health System. METHODS: The
PROCESS study has been used as data source (Kumar 2007,
Manca 2008). 100 patients from 12 European, Canadian and
Australian hospitals (1 Spanish: Sant Pau Hospital, Barcelona),
were randomised to either the SCS or CMM group. Health care
resource consumption data, the implantable generator use in SCS
patients, hospital stay, and drug/non-drug pain-related treatment
were collected prospectively. Resource consumption costs were
obtained from local databases (eSalud and portalfarma data-
bases) using Spanish 2007 ﬁgures. HRQoL was assessed using
EuroQol-5D (EQ-5D) questionnaire and evaluated with Spanish
Time Trade Off tariffs. Both costs and outcomes were assessed
for each patient over the ﬁrst 6-months of the PROCESS trial.
RESULTS: The 6-month mean total health care cost in the SCS
group (€17,291; SD €4.243) was signiﬁcantly higher than in the
CMM group (€1,433; SD€2,088), with a mean difference of
€15,858 (95% CI: 14.548–17.173€). A reduction in drug costs
for SCS group was observed. However, the gain in HRQoL with
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